Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription Articles published in J Urol Retrieve available abstracts of 259 articles: HTML format

Single Articles

November 2023
1. TOSOIAN JJ, Yu A, Brisbane WG
   Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
   J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
   PubMed    
   
   
   
2. JOYCE DD, Filson CP, Herrel LA
   What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
   J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
   PubMed    
   
   
   
3. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
   Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
   J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
   PubMed    
   
   
   
4. LEPOR H
   Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
   J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
   PubMed    
   
   
   
5. CHEN Y, Liang Z, Yan W
   Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
   J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
   PubMed    
   
   
   
6. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
   Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
   J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
   PubMed     Abstract available
   
   
   October 2023
7. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
   Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
   J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
   PubMed     Abstract available
   
   
   
8. TERAMOTO Y, Wang Y, Miyamoto H
   Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
   J Urol. 2023;210:639-648.
   PubMed     Abstract available
   
   
   September 2023
9. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
   Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
   J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
   PubMed    
   
   
   
10. SHAH N, Ioffe V
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
    PubMed    
    
    
    August 2023
11. TANG W, Tang Y, Qi L, Zhang Y, et al
    BPH-related False Positive of PSMA-PET in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?
    J Urol. 2023 Aug 30:101097JU0000000000003680. doi: 10.1097/JU.0000000000003680.
    PubMed     Abstract available
    
    
    
12. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Aug 25:101097JU0000000000003675. doi: 10.1097/JU.0000000000003675.
    PubMed    
    
    
    
13. JOYCE DD, Schulte PJ, Kwon ED, Dusetzina SB, et al
    Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.
    J Urol. 2023;210:290-298.
    PubMed     Abstract available
    
    
    
14. URKMEZ A, Davis JW
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Reply.
    J Urol. 2023;210:249.
    PubMed    
    
    
    
15. OZDEN E, Ozturk E, Turgut AT
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Letter.
    J Urol. 2023;210:248-249.
    PubMed    
    
    
    
16. BERMAN DM, Lee AY, Lesurf R, Patel PG, et al
    Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.
    J Urol. 2023;210:257-271.
    PubMed     Abstract available
    
    
    
17. CHANG K, Greenberg SA, Cowan JE, Parker R, et al
    Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging.
    J Urol. 2023;210:281-289.
    PubMed     Abstract available
    
    
    
18. BRITTON CJ, Sharma V, Fadel AE, Bearrick E, et al
    Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes.
    J Urol. 2023;210:312-322.
    PubMed     Abstract available
    
    
    July 2023
19. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jul 28:101097JU0000000000003633. doi: 10.1097/JU.0000000000003633.
    PubMed    
    
    
    
20. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Jul 14:101097JU0000000000003614. doi: 10.1097/JU.0000000000003614.
    PubMed    
    
    
    
21. 
    MP44-04 Importance of the Ultrasound Characteristics of Regions of Interest by MRI and the Additional Target Biopsy Around Their Peri-hypoechoic Lesions in MR/TRUS Software Fusion Biopsy to Improve Detection Rate of Prostate Cancer.
    J Urol. 2023;210:223.
    PubMed    
    
    
    June 2023
22. YIM K, Ma C, Carlsson S, Lilja H, et al
    Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
    J Urol. 2023 Jun 29:101097JU0000000000003603. doi: 10.1097/JU.0000000000003603.
    PubMed     Abstract available
    
    
    
23. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
    J Urol. 2023 Jun 23:101097JU0000000000003598. doi: 10.1097/JU.0000000000003598.
    PubMed    
    
    
    
24. MAI Z, Zhou Z
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter.
    J Urol. 2023 Jun 22:101097JU0000000000003597. doi: 10.1097/JU.0000000000003597.
    PubMed    
    
    
    
25. JOYCE DD, Qin X, Sharma V, Boorjian SA, et al
    The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
    J Urol. 2023 Jun 21:101097JU0000000000003592. doi: 10.1097/JU.0000000000003592.
    PubMed     Abstract available
    
    
    
26. YANAGISAWA T, Rajwa P, Kawada T, Mori K, et al
    Efficacy of Systemic Treatment in Prostate Cancer Patients with Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    J Urol. 2023 Jun 20:101097JU0000000000003594. doi: 10.1097/JU.0000000000003594.
    PubMed     Abstract available
    
    
    
27. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jun 19:101097JU0000000000003587. doi: 10.1097/JU.0000000000003587.
    PubMed    
    
    
    
28. WYSOCK JS, Rapoport E, Hernandez H, Gogaj R, et al
    Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer.
    J Urol. 2023 Jun 7:101097JU0000000000003569. doi: 10.1097/JU.0000000000003569.
    PubMed     Abstract available
    
    
    
29. BRAILLON A
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Jun 1:101097JU0000000000003567. doi: 10.1097/JU.0000000000003567.
    PubMed    
    
    
    May 2023
30. SHAH N, Ioffe V
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Letter.
    J Urol. 2023 May 30:101097JU0000000000003564. doi: 10.1097/JU.0000000000003564.
    PubMed    
    
    
    
31. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 18:101097JU0000000000003541. doi: 10.1097/JU.0000000000003541.
    PubMed    
    
    
    
32. ANDREWS JR, Sood A, Chapin BF
    Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    J Urol. 2023 May 17:101097JU0000000000003495. doi: 10.1097/JU.0000000000003495.
    PubMed    
    
    
    
33. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 3:101097JU0000000000003477. doi: 10.1097/JU.0000000000003477.
    PubMed    
    
    
    
34. 
    LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol. 2023 May 2:101097JU0000000000003518. doi: 10.1097/JU.0000000000003518.
    PubMed     Abstract available
    
    
    
35. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023;209:1026-1028.
    PubMed    
    
    
    
36. AVOLIO PP, Polascik TJ, Rastinehad A, de la Rosette J, et al
    Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. Letter.
    J Urol. 2023;209:848-849.
    PubMed    
    
    
    
37. SHAH RB
    Point/Counterpoint: Gleason Score 6/Grade Group 1 Prostate Cancer Should Renamed as "Non-cancer" to Improve Public Health-A Wrong Idea From a Pathologist's Perspective.
    J Urol. 2023 May 1:101097JU0000000000003510. doi: 10.1097/JU.0000000000003510.
    PubMed    
    
    
    
38. ZHOU M, Paner GP
    Grade Group 1 (Gleason Score 6) Prostate Cancer Should be Re-named to Improve Public Health: Pathologists' Perspective.
    J Urol. 2023 May 1:101097JU0000000000003511. doi: 10.1097/JU.0000000000003511.
    PubMed    
    
    
    April 2023
39. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 PET in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
    J Urol. 2023 Apr 26:101097JU0000000000003493. doi: 10.1097/JU.0000000000003493.
    PubMed     Abstract available
    
    
    
40. LOWRANCE W, Dreicer R, Jarrard DF, Scarpato KR, et al
    Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).
    J Urol. 2023 Apr 25:101097JU0000000000003452. doi: 10.1097/JU.0000000000003452.
    PubMed     Abstract available
    
    
    
41. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.
    J Urol. 2023 Apr 25:101097JU0000000000003491. doi: 10.1097/JU.0000000000003491.
    PubMed     Abstract available
    
    
    
42. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.
    J Urol. 2023 Apr 25:101097JU0000000000003492. doi: 10.1097/JU.0000000000003492.
    PubMed     Abstract available
    
    
    
43. MARTINI A, Wever L, Soeterik TFW, Rakauskas A, et al
    Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
    J Urol. 2023 Apr 13:101097JU0000000000003442. doi: 10.1097/JU.0000000000003442.
    PubMed     Abstract available
    
    
    
44. BARABAN E, Erak E, Fatima A, Akbari A, et al
    Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
    J Urol. 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.
    PubMed     Abstract available
    
    
    
45. HO MD, Ross AE, Eggener SE
    Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance.
    J Urol. 2023 Apr 12:101097JU0000000000003454. doi: 10.1097/JU.0000000000003454.
    PubMed     Abstract available
    
    
    
46. SHAH N, Ioffe V
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 11:101097JU0000000000003458. doi: 10.1097/JU.0000000000003458.
    PubMed    
    
    
    
47. KA-FUNG CHIU P, Leow JJ, Chiang CH, Mok A, et al
    Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation.
    J Urol. 2023 Apr 10:101097JU0000000000003450. doi: 10.1097/JU.0000000000003450.
    PubMed     Abstract available
    
    
    
48. GUIDOTTI A, Lombardo R, De Nunzio C
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003456. doi: 10.1097/JU.0000000000003456.
    PubMed    
    
    
    
49. HABASHY D, Reddy D, Peters M, Shah TT, et al
    Evaluation of Outcomes following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.
    PubMed     Abstract available
    
    
    
50. 
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2023;209:815.
    PubMed    
    
    
    March 2023
51. BREEN KE, Symecko H, Spielman K, Gebert R, et al
    Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
    J Urol. 2023 Mar 28:101097JU0000000000003186. doi: 10.1097/JU.0000000000003186.
    PubMed     Abstract available
    
    
    
52. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Mar 23:101097JU0000000000003421. doi: 10.1097/JU.0000000000003421.
    PubMed    
    
    
    
53. JIN S, Wu L, Mai Z, Yan W, et al
    A Multicenter, Randomized, Single-Blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
    J Urol. 2023 Mar 16:101097JU0000000000003404. doi: 10.1097/JU.0000000000003404.
    PubMed    
    
    
    
54. ZHANG K, Teoh J, Laguna P, Ng CF, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.
    J Urol. 2023 Mar 16:101097JU0000000000003405. doi: 10.1097/JU.0000000000003405.
    PubMed    
    
    
    
55. SCHNEIDER AC, Chandrasekar T, Bowler N, Fogg R, et al
    Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
    J Urol. 2023 Mar 9:101097JU0000000000003396. doi: 10.1097/JU.0000000000003396.
    PubMed     Abstract available
    
    
    
56. HUSSAIN M, Sternberg CN, Efstathiou E, Fizazi K, et al
    Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
    J Urol. 2023;209:532-539.
    PubMed     Abstract available
    
    
    February 2023
57. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
    The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
    J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
    PubMed     Abstract available
    
    
    
58. LEAPMAN MS, Wang R, Loeb S, Seibert TM, et al
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
    J Urol. 2023 Feb 8:101097JU0000000000003159. doi: 10.1097/JU.0000000000003159.
    PubMed     Abstract available
    
    
    
59. PATEL N, Hughes A, Zhang H, Brisbane W, et al
    Utility of MRI for Localizing Prostate Cancer near the Urethra in Men Who are Candidates for Focal Gland Ablation.
    J Urol. 2023 Feb 8:101097JU0000000000003197. doi: 10.1097/JU.0000000000003197.
    PubMed     Abstract available
    
    
    
60. 
    Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
    J Urol. 2023;209:450.
    PubMed    
    
    
    
61. SCHWEIZER MT, True L, Gulati R, Zhao Y, et al
    Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
    J Urol. 2023;209:354-363.
    PubMed     Abstract available
    
    
    January 2023
62. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2023 Jan 25:101097JU0000000000003180. doi: 10.1097/JU.0000000000003180.
    PubMed    
    
    
    
63. TOUIJER K, Plata Bello A
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
    J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.
    PubMed    
    
    
    
64. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
    J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.
    PubMed    
    
    
    
65. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Expression of Concern: G Protein beta3 Subunit Gene C825T Polymorphism and its Association with the Presence and Clinicopathological Characteristics of Prostate Cancer.
    J Urol. 2023 Jan 10:101097JU0000000000003145. doi: 10.1097/JU.0000000000003145.
    PubMed    
    
    
    
66. CARROLL P
    Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply.
    J Urol. 2023;209:73.
    PubMed    
    
    
    
67. SHOJI S, Kaya T, Tanaka Y, Uemura K, et al
    Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reportin
    J Urol. 2023;209:187-197.
    PubMed     Abstract available
    
    
    December 2022
68. LIN DW
    Point-Counterpoint: Active Surveillance Should Still be Preferred Management for All (or Nearly All) Men with Low Risk Prostate Cancer.
    J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134.
    PubMed    
    
    
    
69. TIMILSHINA N, Alibhai SMH, Tomlinson G, Sander B, et al
    Long-Term Outcomes following Active Surveillance of Low-Grade Prostate Cancer: A Population-Based Study Using a Landmark Approach.
    J Urol. 2022 Dec 7:101097JU0000000000003097. doi: 10.1097/JU.0000000000003097.
    PubMed     Abstract available
    
    
    
70. HIGANO CS, Hafron J
    Adherence With Oral Anticancer Therapies: Clinical Trial versus Real-World Experiences with a Focus on Prostate Cancer.
    J Urol. 2022 Dec 6:101097JU0000000000003081. doi: 10.1097/JU.0000000000003081.
    PubMed     Abstract available
    
    
    
71. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022;208:1349-1351.
    PubMed    
    
    
    
72. ANDREWS JR, Ahmed ME, Sharma V, Britton C, et al
    Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
    J Urol. 2022;208:1240-1249.
    PubMed     Abstract available
    
    
    
73. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003088. doi: 10.1097/JU.0000000000003088.
    PubMed    
    
    
    
74. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003080. doi: 10.1097/JU.0000000000003080.
    PubMed     Abstract available
    
    
    November 2022
75. DE LA ROSETTE J, Dominguez-Escrig J, Zhang K, Teoh J, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
    J Urol. 2022 Nov 28:101097JU0000000000003051. doi: 10.1097/JU.0000000000003051.
    PubMed     Abstract available
    
    
    
76. PITTMAN A, Moses KA, Washington SL 3rd
    Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
    J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
    PubMed    
    
    
    
77. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
    PubMed    
    
    
    
78. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
    PubMed     Abstract available
    
    
    
79. MARTINI A, Valerio M
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
    J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
    PubMed    
    
    
    
80. BOWER PE
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
    J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
    PubMed    
    
    
    
81. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
    Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
    J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
    PubMed     Abstract available
    
    
    
82. OZMAN O, Tillier CN, van Muilekom E, van de Poll-Franse LV, et al
    Financial Toxicity After Robot-Assisted Radical Prostatectomy and Its Relation with Oncologic, Functional Outcomes.
    J Urol. 2022;208:978-986.
    PubMed     Abstract available
    
    
    
83. DOAN P, Scheltema MJ, Amin A, Shnier R, et al
    Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
    J Urol. 2022;208:1028-1036.
    PubMed     Abstract available
    
    
    
84. MAZZONE E, Gandaglia G, Stabile A, Bravi CA, et al
    Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
    J Urol. 2022;208:1046-1055.
    PubMed     Abstract available
    
    
    
85. FILSON CP, Zhu K, Huang Y, Zheng Y, et al
    Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
    J Urol. 2022;208:1037-1045.
    PubMed     Abstract available
    
    
    October 2022
86. PAUDEL R, Madan R, Qi J, Ferrante S, et al
    The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
    PubMed     Abstract available
    
    
    
87. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
    PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
    J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
    PubMed     Abstract available
    
    
    
88. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Oct 10:101097JU0000000000003008. doi: 10.1097/JU.0000000000003008.
    PubMed    
    
    
    
89. BABOUDJIAN M, Ploussard G
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort. Letter.
    J Urol. 2022 Oct 10:101097JU0000000000002991. doi: 10.1097/JU.0000000000002991.
    PubMed    
    
    
    
90. ZATTONI F, Marra G, Kasivisvanathan V, Grummet J, et al
    The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi
    J Urol. 2022;208:830-837.
    PubMed     Abstract available
    
    
    
91. RAVI P, Kwak L, Xie W, Kelleher K, et al
    Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
    J Urol. 2022;208:838-845.
    PubMed     Abstract available
    
    
    
92. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2022;208:846-854.
    PubMed     Abstract available
    
    
    September 2022
93. LABBATE CV, Klotz L, Morrow M, Cooperberg M, et al
    Focal Therapy for Prostate Cancer -Evolutionary Parallels to Breast Cancer Treatment.
    J Urol. 2022 Sep 21:101097JU0000000000002972. doi: 10.1097/JU.0000000000002972.
    PubMed     Abstract available
    
    
    
94. ROULEAU M, Neveu B, Caron P, Morin F, et al
    Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level.
    J Urol. 2022 Sep 14:101097JU0000000000002923. doi: 10.1097/JU.0000000000002923.
    PubMed     Abstract available
    
    
    
95. JOYCE DD, Sharma V, Jiang DH, Van Houten HK, et al
    Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
    J Urol. 2022 Sep 12:101097JU0000000000002856. doi: 10.1097/JU.0000000000002856.
    PubMed     Abstract available
    
    
    
96. LOPEZ BM, Boville GA, Bernardos GB, Marckert XA, et al
    Focal Therapy of Prostate Cancer Index Lesion with Irreversible Electroporation. A Prospective Study with a Median Follow-Up of Three Years.
    J Urol. 2022 Sep 8:101097JU0000000000002970. doi: 10.1097/JU.0000000000002970.
    PubMed     Abstract available
    
    
    
97. DE LA CALLE CM, Mamawala MM, Landis P, Macura KJ, et al
    Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2022 Sep 8:101097JU0000000000002963. doi: 10.1097/JU.0000000000002963.
    PubMed     Abstract available
    
    
    
98. SHEE K, Washington SL 3rd, Cowan JE, de la Calle CM, et al
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort.
    J Urol. 2022 Sep 6:101097JU0000000000002956. doi: 10.1097/JU.0000000000002956.
    PubMed     Abstract available
    
    
    
99. SHIRK JD, Reiter R, Wallen EM, Pak R, et al
    Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.
    J Urol. 2022;208:618-625.
    PubMed     Abstract available
    
    
    August 2022
100. DE B, Pasalic D, Barocas DA, Wallis CJD, et al
     Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study.
     J Urol. 2022 Aug 25:101097JU0000000000002902. doi: 10.1097/JU.0000000000002902.
     PubMed     Abstract available
     
     
     
101. TROCK BJ, Jing Y, Mabey B, Sangale Z, et al
     Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy.
     J Urol. 2022 Aug 25:101097JU0000000000002922. doi: 10.1097/JU.0000000000002922.
     PubMed    
     
     
     
102. KIM IE JR, Pareek G
     The Key to Addressing Disparities in Prostate Cancer: Urologists in Advocacy?
     J Urol. 2022 Aug 24:101097JU0000000000002930. doi: 10.1097/JU.0000000000002930.
     PubMed    
     
     
     
103. RACHUBINSKI P, Witt JH, Budaus L, Zinke J, et al
     Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions.
     J Urol. 2022 Aug 24:101097JU0000000000002921. doi: 10.1097/JU.0000000000002921.
     PubMed     Abstract available
     
     
     
104. GABRIELSON AT, Choi U, Fletcher SA, Pavlovich CP, et al
     Lost in Transparency: The 21st Century Cures Act ("Open Notes") and Prostate Cancer Care.
     J Urol. 2022 Aug 19:101097JU0000000000002924. doi: 10.1097/JU.0000000000002924.
     PubMed    
     
     
     
105. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Aug 19:101097JU0000000000002909. doi: 10.1097/JU.0000000000002909.
     PubMed    
     
     
     
106. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Aug 16:101097JU0000000000002870. doi: 10.1097/JU.0000000000002870.
     PubMed    
     
     
     
107. ABUSAMRA SM, Solorzano MA, Luke M, Quarles J, et al
     Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.
     J Urol. 2022 Aug 5:101097JU0000000000002865. doi: 10.1097/JU.0000000000002865.
     PubMed     Abstract available
     
     
     
108. GLOGER S, Ubrig B, Boy A, Leyh-Bannurah SR, et al
     Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
     J Urol. 2022;208:333-340.
     PubMed     Abstract available
     
     
     
109. GOODE PS, Johnson TM 2nd, Newman DK, Vaughan CP, et al
     Perioperative Mobile Telehealth Program for Post-Prostatectomy Incontinence: A Randomized Clinical Trial.
     J Urol. 2022;208:379-387.
     PubMed     Abstract available
     
     
     
110. ABOU ZEINAB M, Beksac AT, Corse T, Talamini S, et al
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management.
     J Urol. 2022;208:369-378.
     PubMed     Abstract available
     
     
     July 2022
111. BRANT A, Lewicki P, Wu X, Sze C, et al
     Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer.
     J Urol. 2022 Jul 28:101097JU0000000000002857. doi: 10.1097/JU.0000000000002857.
     PubMed     Abstract available
     
     
     
112. EASTHAM JA, Boorjian SA, Kirkby E
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
     J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.
     PubMed    
     
     
     
113. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
     The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
     J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
     PubMed     Abstract available
     
     
     
114. FAN S, Zhang Z, Wang J, Xiong S, et al
     Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
     J Urol. 2022;208:119-127.
     PubMed     Abstract available
     
     
     
115. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
     The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
     J Urol. 2022;208:109-118.
     PubMed     Abstract available
     
     
     June 2022
116. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
     Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
     J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
     PubMed     Abstract available
     
     
     
117. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.
     PubMed    
     
     
     
118. XUE X, Yang X, Ji Z, Xie Y, et al
     Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. Letter.
     J Urol. 2022 Jun 21:101097JU0000000000002830. doi: 10.1097/JU.0000000000002830.
     PubMed    
     
     
     
119. ABOU ZEINAB M, Kaouk J
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply.
     J Urol. 2022 Jun 3:101097JU0000000000002785. doi: 10.1097/JU.0000000000002785.
     PubMed    
     
     
     
120. TIAN Y, Zhang H, Luo G
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter.
     J Urol. 2022 Jun 3:101097JU0000000000002784. doi: 10.1097/JU.0000000000002784.
     PubMed    
     
     
     
121. TURCHAN WT, Cutright D, Wu T, Leng JX, et al
     Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
     J Urol. 2022;207:1236-1245.
     PubMed     Abstract available
     
     
     May 2022
122. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 May 20:101097JU0000000000002745. doi: 10.1097/JU.0000000000002745.
     PubMed    
     
     
     
123. STEPHENSON AJ, Vourganti S
     Pro: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
     J Urol. 2022 May 12:101097JU0000000000002776. doi: 10.1097/JU.0000000000002776.
     PubMed    
     
     
     
124. SIDDIQUI MM
     Con: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
     J Urol. 2022 May 12:101097JU0000000000002777. doi: 10.1097/JU.0000000000002777.
     PubMed    
     
     
     
125. COLE AP, Chen X, Langbein BJ, Giganti F, et al
     Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis.
     J Urol. 2022 May 10:101097JU0000000000002736. doi: 10.1097/JU.0000000000002736.
     PubMed     Abstract available
     
     
     
126. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up.
     J Urol. 2022 May 10:101097JU0000000000002758. doi: 10.1097/JU.0000000000002758.
     PubMed     Abstract available
     
     
     
127. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.
     J Urol. 2022 May 10:101097JU0000000000002757. doi: 10.1097/JU.0000000000002757.
     PubMed     Abstract available
     
     
     
128. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.
     J Urol. 2022 May 10:101097JU0000000000002759. doi: 10.1097/JU.0000000000002759.
     PubMed     Abstract available
     
     
     
129. ZHANG Y, Song M, Mucci LA, Giovannucci EL, et al
     Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.
     J Urol. 2022 May 6:101097JU0000000000002735. doi: 10.1097/JU.0000000000002735.
     PubMed     Abstract available
     
     
     
130. RADHAKRISHNAN A, Wallner LP, Skolarus TA, George AK, et al
     Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
     J Urol. 2022 May 6:101097JU0000000000002734. doi: 10.1097/JU.0000000000002734.
     PubMed     Abstract available
     
     
     
131. 
     Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Im
     J Urol. 2022;207:1166.
     PubMed    
     
     
     
132. GONDOPUTRO W, Thompson J, Evans M, Bolton D, et al
     How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.
     J Urol. 2022;207:1048-1056.
     PubMed     Abstract available
     
     
     April 2022
133. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Apr 25:101097JU0000000000002705. doi: 10.1097/JU.0000000000002705.
     PubMed    
     
     
     
134. FRANLUND M, Mansson M, Godtman RA, Aus G, et al
     Results from 22 years of Follow-Up in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial.
     J Urol. 2022 Apr 15:101097JU0000000000002696. doi: 10.1097/JU.0000000000002696.
     PubMed     Abstract available
     
     
     
135. LEWICKI P, Brant A, Shoag JE
     Re: A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
     J Urol. 2022 Apr 8:101097JU0000000000002700. doi: 10.1097/JU.0000000000002700.
     PubMed    
     
     
     
136. NYAME YA, Schraidt JA, Chakoian M, Nissenberg MG, et al
     A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
     J Urol. 2022 Apr 8:101097JU0000000000002694. doi: 10.1097/JU.0000000000002694.
     PubMed     Abstract available
     
     
     
137. JIBARA GA, Perera M, Vertosick EA, Sjoberg DD, et al
     Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.
     J Urol. 2022 Apr 4:101097JU0000000000002668. doi: 10.1097/JU.0000000000002668.
     PubMed     Abstract available
     
     
     
138. DASKIVICH TJ, Gale R, Luu M, Naser-Tavakolian A, et al
     Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
     J Urol. 2022 Apr 4:101097JU0000000000002675. doi: 10.1097/JU.0000000000002675.
     PubMed     Abstract available
     
     
     
139. PERERA M, Assel MJ, Benfante NE, Vickers AJ, et al
     Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
     J Urol. 2022 Apr 1:101097JU0000000000002685. doi: 10.1097/JU.0000000000002685.
     PubMed     Abstract available
     
     
     March 2022
140. MONTORSI F, Mazzone E, Gandaglia G, Stabile A, et al
     Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
     J Urol. 2022 Mar 29:101097JU0000000000002680. doi: 10.1097/JU.0000000000002680.
     PubMed    
     
     
     
141. CHIERIGO F, Borghesi M, Mantica G, Terrone C, et al
     Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply.
     J Urol. 2022 Mar 29:101097JU0000000000002681. doi: 10.1097/JU.0000000000002681.
     PubMed    
     
     
     
142. DURSUN F, Wang CP, MacCarthy D, Mansour AM, et al
     Absolute PSA after 6 Months of Androgen Deprivation Therapy is a Predictor of Overall and Cancer Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
     J Urol. 2022 Mar 28:101097JU0000000000002676. doi: 10.1097/JU.0000000000002676.
     PubMed     Abstract available
     
     
     
143. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Mar 17:101097JU0000000000002511. doi: 10.1097/JU.0000000000002511.
     PubMed    
     
     
     
144. BRIGHT JR, Lis RT, Ku AT, Terrigino NT, et al
     PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
     J Urol. 2022 Mar 1:101097JU0000000000002492. doi: 10.1097/JU.0000000000002492.
     PubMed     Abstract available
     
     
     
145. KAN KM, Tin AL, Stearns GL, Eastham JA, et al
     De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors.
     J Urol. 2022;207:601-608.
     PubMed     Abstract available
     
     
     
146. BAHOUTH Z, Laniado M, Fowler R, Charlesworth PJS, et al
     Positive Surgical Margins Rate of Retzius-Sparing Robot-Assisted Radical Prostatectomy in a Contemporary, Unselected Cohort.
     J Urol. 2022;207:609-616.
     PubMed     Abstract available
     
     
     February 2022
147. KAWA SM, Stroomberg HV, Larsen SB, Helgstrand JT, et al
     A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
     J Urol. 2022 Feb 25:101097JU0000000000002491. doi: 10.1097/JU.0000000000002491.
     PubMed     Abstract available
     
     
     
148. MAGNANI CJ, Hernandez-Boussard T, Baker LC, Goldhaber-Fiebert JD, et al
     Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
     J Urol. 2022 Feb 25:101097JU0000000000002490. doi: 10.1097/JU.0000000000002490.
     PubMed     Abstract available
     
     
     
149. KANG DW, Fairey AS, Boule NG, Field CJ, et al
     A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
     J Urol. 2022 Feb 17:101097JU0000000000002334. doi: 10.1097/JU.0000000000002334.
     PubMed     Abstract available
     
     
     
150. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Feb 16:101097JU0000000000002477. doi: 10.1097/JU.0000000000002477.
     PubMed    
     
     
     
151. LOEB S, Borno HT, Gomez S, Ravenell J, et al
     Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.
     J Urol. 2022 Feb 4:101097JU0000000000002257. doi: 10.1097/JU.0000000000002257.
     PubMed     Abstract available
     
     
     
152. KACHANOV M, Leyh-Bannurah SR, Roberts MJ, Sauer M, et al
     Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
     J Urol. 2022;207:333-340.
     PubMed     Abstract available
     
     
     
153. OTLES E, Denton BT, Qu B, Murali A, et al
     Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.
     J Urol. 2022;207:358-366.
     PubMed     Abstract available
     
     
     
154. CLEMENTS MB, Tin AL, Estes CL, Jibara G, et al
     Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.
     J Urol. 2022;207:367-374.
     PubMed     Abstract available
     
     
     January 2022
155. ANDRUSKA N, Fischer-Valuck BW, Waters M, Diaz EJ, et al
     Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-only versus Whole Pelvic Radiation Therapy.
     J Urol. 2022 Jan 27:101097JU0000000000002455. doi: 10.1097/JU.0000000000002455.
     PubMed     Abstract available
     
     
     
156. KUPPERMANN D, Calais J, Marks LS
     Imaging Prostate Cancer: Clinical Utility of Prostate-specific Membrane Antigen (PSMA).
     J Urol. 2022 Jan 27:101097JU0000000000002457. doi: 10.1097/JU.0000000000002457.
     PubMed     Abstract available
     
     
     
157. SCHIFF H
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Letter.
     J Urol. 2022 Jan 26:101097JU0000000000002456. doi: 10.1097/JU.0000000000002456.
     PubMed    
     
     
     
158. ROSENBERG JE, Jarosek S, Spilseth B, Huang YH, et al
     Diagnosing Prostate Cancer: The Role of Intravesicular Prostatic Gland Protrusion on Accuracy of Prostate Biopsies.
     J Urol. 2022 Jan 26:101097JU0000000000002448. doi: 10.1097/JU.0000000000002448.
     PubMed     Abstract available
     
     
     
159. EGGENER S, Siemens DR
     Prostate Cancer, Decisional Regret and Exercise.
     J Urol. 2022 Jan 26:101097JU0000000000002453. doi: 10.1097/JU.0000000000002453.
     PubMed    
     
     
     
160. WANG M, Semerjian A, Lane BR, George AK, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
     J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
     PubMed    
     
     
     
161. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
     Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
     J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
     PubMed     Abstract available
     
     
     
162. SHAHAIT M, Cheaib JG, Davicioni E, Liu Y, et al
     Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score?
     J Urol. 2022 Jan 20:101097JU0000000000002440. doi: 10.1097/JU.0000000000002440.
     PubMed     Abstract available
     
     
     
163. PAN A, Reingold RE, Zhao JL, Moy A, et al
     Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
     J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
     PubMed     Abstract available
     
     
     
164. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
     PubMed    
     
     
     
165. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
     Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
     J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
     PubMed     Abstract available
     
     
     
166. NAYAK JG
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
     J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
     PubMed    
     
     
     
167. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
     J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
     PubMed    
     
     
     
168. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
     The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
     J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
     PubMed     Abstract available
     
     
     
169. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
     Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
     J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
     PubMed     Abstract available
     
     
     
170. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
     Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
     J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
     PubMed     Abstract available
     
     
     
171. LEE A, Chen K, Tay KJ
     Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
     J Urol. 2022;207:240-241.
     PubMed    
     
     
     
172. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
     J Urol. 2022;207:241-242.
     PubMed    
     
     
     
173. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
     Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
     J Urol. 2022;207:118-126.
     PubMed     Abstract available
     
     
     
174. CHANG P, Wagner AA, Regan MM, Smith JA, et al
     Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
     J Urol. 2022;207:127-136.
     PubMed     Abstract available
     
     
     
175. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
     Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
     J Urol. 2022;207:95-107.
     PubMed     Abstract available
     
     
     
176. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
     Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
     J Urol. 2022;207:108-117.
     PubMed     Abstract available
     
     
     December 2021
177. WASHINGTON SL 3RD, Gore JL, Nyame YA
     Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
     J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
     PubMed    
     
     
     
178. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
     Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
     J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
     PubMed     Abstract available
     
     
     
179. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
     PubMed    
     
     
     
180. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
     Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
     PubMed     Abstract available
     
     
     
181. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
     Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
     PubMed     Abstract available
     
     
     
182. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
     MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
     PubMed     Abstract available
     
     
     
183. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
     J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
     PubMed     Abstract available
     
     
     
184. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
     Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
     J Urol. 2021;206:1403-1410.
     PubMed     Abstract available
     
     
     November 2021
185. CHEN K, Murphy D, Lawrentschuk N
     Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
     J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
     PubMed    
     
     
     
186. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
     PubMed    
     
     
     
187. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
     Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
     J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
     PubMed    
     
     
     
188. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
     Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
     J Urol. 2021;206:1192-1203.
     PubMed     Abstract available
     
     
     
189. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
     Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
     J Urol. 2021;206:1184-1191.
     PubMed     Abstract available
     
     
     October 2021
190. LEE MC, Erickson TR, Stock S, Howard LE, et al
     Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
     PubMed     Abstract available
     
     
     
191. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
     Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
     J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
     PubMed     Abstract available
     
     
     
192. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
     Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
     PubMed     Abstract available
     
     
     
193. YU W, Guo J
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
     J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
     PubMed    
     
     
     
194. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
     Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
     PubMed     Abstract available
     
     
     
195. 
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
     PubMed    
     
     
     
196. KAPLAN-MARANS E
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
     J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
     PubMed    
     
     
     
197. ZHANG KW, Guha A
     Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
     J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
     PubMed    
     
     
     
198. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
     Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
     J Urol. 2021;206:894-902.
     PubMed     Abstract available
     
     
     
199. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
     A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
     J Urol. 2021;206:942-951.
     PubMed     Abstract available
     
     
     September 2021
200. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
     J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
     PubMed     Abstract available
     
     
     
201. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
     Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
     J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
     PubMed     Abstract available
     
     
     
202. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
     An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
     J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
     PubMed     Abstract available
     
     
     
203. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
     (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
     J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
     PubMed     Abstract available
     
     
     
204. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
     Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
     J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
     PubMed     Abstract available
     
     
     
205. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
     Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
     J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
     PubMed    
     
     
     
206. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
     PubMed    
     
     
     
207. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
     Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
     J Urol. 2021;206:706-714.
     PubMed     Abstract available
     
     
     
208. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
     The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
     J Urol. 2021;206:662-668.
     PubMed     Abstract available
     
     
     
209. HINES L, Zhu D, DeMasi M, Babar M, et al
     A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
     J Urol. 2021;206:586-594.
     PubMed     Abstract available
     
     
     
210. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
     Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
     J Urol. 2021;206:604-612.
     PubMed     Abstract available
     
     
     August 2021
211. KIM M, Wu S, Lin SX, Crotty RK, et al
     Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
     J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
     PubMed     Abstract available
     
     
     
212. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
     Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
     J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
     PubMed     Abstract available
     
     
     
213. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
     PubMed    
     
     
     
214. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
     Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
     J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
     PubMed     Abstract available
     
     
     
215. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
     Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
     J Urol. 2021;206:325-337.
     PubMed     Abstract available
     
     
     
216. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
     J Urol. 2021;206:289-297.
     PubMed     Abstract available
     
     
     
217. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
     Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
     J Urol. 2021;206:346-353.
     PubMed     Abstract available
     
     
     July 2021
218. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
     J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
     PubMed     Abstract available
     
     
     
219. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
     PubMed    
     
     
     
220. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
     Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
     J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
     PubMed     Abstract available
     
     
     
221. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
     Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
     J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
     PubMed     Abstract available
     
     
     
222. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
     Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
     J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
     PubMed     Abstract available
     
     
     June 2021
223. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
     Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
     J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
     PubMed     Abstract available
     
     
     
224. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
     J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
     PubMed     Abstract available
     
     
     
225. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
     The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
     J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
     PubMed     Abstract available
     
     
     
226. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
     PubMed    
     
     
     
227. INABA H, Kimura T, Onuma H, Kido M, et al
     Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
     J Urol. 2021;205:1841-1842.
     PubMed    
     
     
     
228. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
     Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
     J Urol. 2021;205:1839-1840.
     PubMed    
     
     
     
229. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
     Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
     J Urol. 2021;205:1663-1670.
     PubMed     Abstract available
     
     
     
230. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
     National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
     J Urol. 2021;205:1641-1647.
     PubMed     Abstract available
     
     
     
231. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
     Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
     J Urol. 2021;205:1681-1688.
     PubMed     Abstract available
     
     
     May 2021
232. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
     Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
     J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
     PubMed     Abstract available
     
     
     
233. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
     Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
     J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
     PubMed     Abstract available
     
     
     
234. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
     Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
     J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
     PubMed     Abstract available
     
     
     
235. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
     Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
     J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
     PubMed     Abstract available
     
     
     
236. MACDONALD S, Matos A, Wambier C
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
     J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
     PubMed    
     
     
     
237. KLEIN EA
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
     J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
     PubMed    
     
     
     
238. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
     PubMed    
     
     
     
239. SHAH N, Ioffe V
     Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
     J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
     PubMed    
     
     
     
240. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
     J Urol. 2021;205:1528-1529.
     PubMed    
     
     
     
241. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
     J Urol. 2021;205:1526-1528.
     PubMed    
     
     
     
242. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
     Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
     J Urol. 2021;205:1344-1351.
     PubMed     Abstract available
     
     
     
243. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
     Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
     J Urol. 2021;205:1444-1451.
     PubMed     Abstract available
     
     
     April 2021
244. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
     Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
     J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
     PubMed     Abstract available
     
     
     
245. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
     Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
     J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
     PubMed     Abstract available
     
     
     
246. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
     Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
     J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
     PubMed     Abstract available
     
     
     
247. FAN L, Fei X, Zhu Y, Chi C, et al
     Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
     J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
     PubMed     Abstract available
     
     
     
248. RAJWA P, Mori K, Huebner NA, Martin DT, et al
     The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
     J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
     PubMed     Abstract available
     
     
     
249. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
     Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
     J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
     PubMed     Abstract available
     
     
     
250. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
     PubMed    
     
     
     
251. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
     J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
     PubMed     Abstract available
     
     
     
252. LIN PH, Howard L, Freedland SJ
     Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
     J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
     PubMed    
     
     
     
253. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
     Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
     J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
     PubMed     Abstract available
     
     
     
254. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
     Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
     J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
     PubMed     Abstract available
     
     
     March 2021
255. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
     Performance of Prostate Health Index in Biopsy Naive Black Men.
     J Urol. 2021;205:718-724.
     PubMed     Abstract available
     
     
     
256. UMARI P, Eden C, Cahill D, Rizzo M, et al
     Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
     J Urol. 2021;205:780-790.
     PubMed     Abstract available
     
     
     
257. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
     Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
     J Urol. 2021;205:732-739.
     PubMed     Abstract available
     
     
     
258. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
     J Urol. 2021;205:748-754.
     PubMed     Abstract available
     
     
     
259. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
     Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
     J Urol. 2021;205:740-747.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.